HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: 291/4/H1545    most recent 01124.2005v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (10) Citing Articles via Google Scholar Google Scholar Articles by Pillai, J. B. Articles by Gupta, M. P. Search for Related Content PubMed PubMed Citation Articles by Pillai, J. B. Articles by Gupta, M. P.

Poly(ADP-ribose) polymerase-1-deficient mice are protected from angiotensin II-induced cardiac hypertrophy

Departments of ¹Surgery and ²Cardiology, and ³Committee on Molecular Medicine and Pathology, The University of Chicago, Chicago, Illinois; and ⁴The Heart Institute of Children, Hope Children Hospital, Oak Lawn, Illinois

Submitted 24 October 2005 ; accepted in final form 12 April 2006

Poly(ADP-ribose) polymerase-1 (PARP), a chromatin-bound enzyme, is activated by cell oxidative stress. Because oxidative stress is also considered a main component of angiotensin II-mediated cell signaling, it was postulated that PARP could be a downstream target of angiotensin II-induced signaling leading to cardiac hypertrophy. To determine a role of PARP in angiotensin II-induced hypertrophy, we infused angiotensin II into wild-type (PARP^+/+) and PARP-deficient mice. Angiotensin II infusion significantly increased heart weight-to-tibia length ratio, myocyte cross-sectional area, and interstitial fibrosis in PARP^+/+ but not in PARP^–/– mice. To confirm these results, we analyzed the effect of angiotensin II in primary cultures of cardiomyocytes. When compared with PARP^–/– cardiomyocytes, angiotensin II (1 µM) treatment significantly increased protein synthesis in PARP^+/+ myocytes, as measured by ³H-leucine incorporation into total cell protein. Angiotensin II-mediated hypertrophy of myocytes was accompanied with increased poly-ADP-ribosylation of nuclear proteins and depletion of cellular NAD content. When cells were treated with cell death-inducing doses of angiotensin II (10–20 µM), robust myocyte cell death was observed in PARP^+/+ but not in PARP^–/– myocytes. This type of cell death was blocked by repletion of cellular NAD levels as well as by activation of the longevity factor Sir2 deacetylase, indicating that PARP induction and subsequent depletion of NAD levels are the sequence of events causing angiotensin II-mediated cardiomyocyte cell death. In conclusion, these results demonstrate that PARP is a nuclear integrator of angiotensin II-mediated cell signaling contributing to cardiac hypertrophy and suggest that this could be a novel therapeutic target for the management of heart failure.

heart failure; oxidative-stress signaling

This article has been cited by other articles:

				H. D. Xiao, S. Fuchs, E. A. Bernstein, P. Li, D. J. Campbell, and K. E. Bernstein Mice expressing ACE only in the heart show that increased cardiac angiotensin II is not associated with cardiac hypertrophy Am J Physiol Heart Circ Physiol, February 1, 2008; 294(2): H659 - H667. [Abstract] [Full Text] [PDF]